Handelsman, Y., Mathieu, C., Del Prato, S., Johnsson, E., Kurlyandskaya, R., Iqbal, N., . . . Rosenstock, J. (2019). Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab.

Handelsman, Yehuda, Chantal Mathieu, Stefano Del Prato, Eva Johnsson, Raisa Kurlyandskaya, Nayyar Iqbal, Ricardo Garcia‐Sanchez, i Julio Rosenstock. "Sustained 52‐week Efficacy and Safety of Triple Therapy With Dapagliflozin Plus Saxagliptin Versus Dual Therapy With Sitagliptin Added to Metformin in Patients With Uncontrolled Type 2 Diabetes." Diabetes Obes Metab 2019.

Handelsman, Yehuda, et al. "Sustained 52‐week Efficacy and Safety of Triple Therapy With Dapagliflozin Plus Saxagliptin Versus Dual Therapy With Sitagliptin Added to Metformin in Patients With Uncontrolled Type 2 Diabetes." Diabetes Obes Metab 2019.